Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan 1:2019:3905817.
doi: 10.1155/2019/3905817. eCollection 2019.

Prognostic Value of CD133 and SOX2 in Advanced Cancer

Susu Han  1 , Tao Huang  2 , Xing Wu  1 , Xiyu Wang  1 , Shanshan Liu  1 , Wei Yang  1 , Qi Shi  1 , Hongjia Li  1 , Fenggang Hou  1
Affiliations

Prognostic Value of CD133 and SOX2 in Advanced Cancer

Susu Han et al. J Oncol. .

Abstract

Background: The prognostic value of CD133 and SOX2 expression in advanced cancer remains unclear. This study was first conducted to investigate the association between CD133 or SOX2 positivity and clinical outcomes for advanced cancer patients.

Methods: Hazard ratios (HRs) with 95% confidence intervals (95% CIs) were calculated to evaluate the correlation between CD133 or SOX2 positivity and overall survival (OS), disease-free survival (DFS), progression-free survival (PFS), cancer-specific survival (CSS), or recurrence-free survival (RFS) from multivariable analysis. Trial sequential analysis (TSA) was also performed.

Results: 13 studies with 1358 cases (CD133) and five studies with 433 cases (SOX2) were identified. CD133 positivity was correlated with worse CSS and OS, but there was no correlation between CD133 positivity and DFS. SOX2 positivity was associated with poor DFS and RFS but was not linked to PFS. Stratified analysis by study source showed that only CD133 positivity can decrease OS for Chinese patients. Stratified analysis by treatment regimens indicated that CD133 positivity was linked to poor OS in patients treated with adjuvant therapy. TSA showed that additional studies were necessary.

Conclusions: CD133 and SOX2 might be associated with worse prognosis in advanced cancer. More prospective studies are strongly needed.

Impact: CD133 and SOX2 may be promising targeted molecular therapy for advanced cancer patients.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow chart for identification of eligible studies.
Figure 2
Figure 2
Forest plot for the correlation between CD133 positive expression and cancer-specific survival (CSS) and disease-free survival (DFS).
Figure 3
Figure 3
Forest plot for the correlation between CD133 positive expression and overall survival (OS).
Figure 4
Figure 4
Forest plot for the association between SOX2 positivity and disease-free survival (DFS), relapse/recurrence-free survival (RFS), and progression-free survival (PFS).
Figure 5
Figure 5
Trial sequential analysis (TSA) for cancer-specific survival (CSS) and overall survival (OS) of CD133 positive expression (α = 5%, β = 20%, and the relative risk reduction (RRR) = 20%).
Figure 6
Figure 6
Trial sequential analysis (TSA) for cancer-specific survival (CSS) and overall survival (OS) of CD133 positive expression (α = 5%, β = 10%, and the relative risk reduction (RRR) = 20%).
Figure 7
Figure 7
Trial sequential analysis (TSA) for cancer-specific survival (CSS) and overall survival (OS) of CD133 positive expression (α = 5%, β = 20%, and the relative risk reduction (RRR) = 15%).
See this image and copyright information in PMC

References

    1. Torre L. A., Bray F., Siegel R. L., Ferlay J., Lortet-Tieulent J. Global cancer statistics, 2012. CA: A Cancer Journal for Clinicians. 2015;65(2):87–108. doi: 10.3322/caac.21262. - DOI - PubMed
    1. Urruticoechea A., Alemany R., Balart J., Villanueva A., Viñals F., Capellá G. Recent advances in cancer therapy: An overview. Current Pharmaceutical Design. 2010;16(1):3–10. doi: 10.2174/138161210789941847. - DOI - PubMed
    1. Kroeze S. G. C., Fritz C., Hoyer M., et al. Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: A systematic review. Cancer Treatment Reviews. 2017;53:25–37. doi: 10.1016/j.ctrv.2016.11.013. - DOI - PubMed
    1. Siegel R. L., Sahar L., Portier K. M., Ward E. M., Jemal A. Cancer death rates in US congressional districts. CA: A Cancer Journal for Clinicians. 2015;65(5):339–344. doi: 10.3322/caac.21292. - DOI - PubMed
    1. Pardoll D. M. The blockade of immune checkpoints in cancer immunotherapy. Nature Reviews Cancer. 2012;12(4):252–264. doi: 10.1038/nrc3239. - DOI - PMC - PubMed